{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:49:52Z","timestamp":1774061392446,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Salivary gland carcinomas (SGCs) represent various groups of tumors that demonstrate marked diversity in their prognosis owing to different histology and clinical characteristics. One of the poor prognostic indicators is distant metastasis which is considered the major reason for death in SGC patients. Discovering new biomarkers is urgently required to aid in the detection of cancer onset and progression. Cathepsin K (CTSK), the lysosomal cysteine protease has a principal role in cancer invasion and progression through interaction with the tumor microenvironment, degradation of extracellular membrane proteins and destruction of the elastic lamina of blood vessels. In the English literature, little information was present about the role of CTSK in SGCs. The current study aimed to assess the immunohistochemical expression of CTSK in SGCs and correlate its expression to different clinicopathologic parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The retrospective study applied to 45 cases of SGCs categorized as high-grade (33 cases) and low-grade SGCs (12 cases) following the criteria of WHO classification (2017) of head and neck tumors. All patients` clinicopathological and follow-up records were retrieved. The following statistical tests were used to study the variance of CTSK expression in SGCs concerning different clinicopathological parameters; Pearson`s Chi-square test, unpaired two-tailed student t-test, One-way ANOVA, and Post Hoc tests. Disease-free survival (DFS) and Overall survival (OS) were calculated and displayed with the Kaplan\u2013Meier strategy and analyzed with the log-rank test. Univariate and multivariate survival analyses were performed with Cox regression. A <jats:italic>P<\/jats:italic>-value lesser than 0.05 was considered statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Strong CTSK expression was significantly related to high-grade SGCs (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), large infiltrating carcinomas (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), presence of nodal (<jats:italic>P<\/jats:italic>\u2009=\u20090.041) and distant metastasis (<jats:italic>P<\/jats:italic>\u2009=\u20090.009), advanced TNM clinical stage (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), the incidence of recurrence (<jats:italic>P<\/jats:italic>\u2009=\u20090.009), and reduced DFS (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). Distant metastasis was the independent predictor for DFS using Cox regression model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CTSK has a great role in cancer progression by triggering many signaling pathways. Its level in cancerous tissue is considered an effective index for predicting the severity and prognosis of cancer. Therefore, we indicate its utility as a prognostic tool and therapeutic target for cancer treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-023-01353-5","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:02:01Z","timestamp":1684296121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological correlation of Cathepsin K expression in salivary gland carcinomas; relation to patients` outcome"],"prefix":"10.1186","volume":"18","author":[{"given":"Heba Ahmed","family":"Elhendawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"issue":"11","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.joms.2006.11.025","volume":"65","author":"MH Ansari","year":"2007","unstructured":"Ansari MH. Salivary gland tumors in an Iranian population: a retrospective study of 130 cases. J Oral Maxillofac Surg. 2007;65(11):2187\u201394.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"1353_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.oraloncology.2007.05.010","volume":"44","author":"A Jones","year":"2008","unstructured":"Jones A, Craig G, Speight P, Franklin C. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol. 2008;44(4):407\u201317.","journal-title":"Oral Oncol"},{"key":"1353_CR3","doi-asserted-by":"publisher","first-page":"187623","DOI":"10.1155\/2011\/187623","volume":"2011","author":"R Murase","year":"2011","unstructured":"Murase R, Sumida T, Ishikawa A, Murase R, McAllister SD, Hamakawa H, et al. Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol. 2011;2011:187623.","journal-title":"Int J Otolaryngol"},{"key":"1353_CR4","volume-title":"Oral and maxillofacial pathology: Elsevier Health Sciences","author":"BW Neville","year":"2015","unstructured":"Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology: Elsevier Health Sciences. 2015."},{"issue":"10","key":"1353_CR5","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/hed.21629","volume":"33","author":"I Sultan","year":"2011","unstructured":"Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A. Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck. 2011;33(10):1476\u201381.","journal-title":"Head Neck"},{"issue":"12","key":"1353_CR6","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1245\/s10434-010-1165-2","volume":"17","author":"ME Kupferman","year":"2010","unstructured":"Kupferman ME, de la Garza GO, Santillan AA, Williams MD, Varghese BT, Huh W, et al. Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol. 2010;17(12):3301\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.21083","volume":"103","author":"WM Mendenhall","year":"2005","unstructured":"Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer. 2005;103(12):2544\u201350.","journal-title":"Cancer"},{"issue":"4","key":"1353_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2559.2011.03777.x","volume":"58","author":"S Schwarz","year":"2011","unstructured":"Schwarz S, Stiegler C, M\u00fcller M, Ettl T, Brockhoff G, Zenk J, et al. Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t (11; 19) translocation. Histopathology. 2011;58(4):557\u201370.","journal-title":"Histopathology"},{"issue":"8","key":"1353_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bjoms.2009.03.017","volume":"47","author":"PM Speight","year":"2009","unstructured":"Speight PM, Barrett AW. Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg. 2009;47(8):587\u201393.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"2","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","volume":"74","author":"M Guzzo","year":"2010","unstructured":"Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74(2):134\u201348.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1353_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000442139","volume":"78","author":"TA Glazer","year":"2016","unstructured":"Glazer TA, Shuman AG. Distant metastases and palliative care. Salivary Gland Neoplasms. 2016;78:182\u20138.","journal-title":"Salivary Gland Neoplasms"},{"issue":"3","key":"1353_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.coms.2017.03.008","volume":"29","author":"RA Ord","year":"2017","unstructured":"Ord RA, Ghazali N. Margin analysis: malignant salivary gland neoplasms of the head and neck. Oral Maxillofac Surg Clin. 2017;29(3):315\u201324.","journal-title":"Oral Maxillofac Surg Clin"},{"issue":"8","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/1097-0142(19841015)54:8<1620::AID-CNCR2820540824>3.0.CO;2-I","volume":"54","author":"RE Hickman","year":"1984","unstructured":"Hickman RE, Cawson RA, Duffy SW. The prognosis of specific types of salivary gland tumors. Cancer. 1984;54(8):1620\u20134.","journal-title":"Cancer"},{"issue":"1","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-016-0919-0","volume":"14","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang S, Zhou X, Zhou H, Cui Y, Li Q, et al. Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. World J Surg Oncol. 2016;14(1):1\u20138.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1353_CR15","doi-asserted-by":"publisher","first-page":"E1125","DOI":"10.1002\/lary.28966","volume":"131","author":"P Moon","year":"2021","unstructured":"Moon P, Tusty M, Divi V, Megwalu UC. Significance of nodal metastasis in parotid gland acinar cell carcinoma. Laryngoscope. 2021;131(4):E1125\u20139.","journal-title":"Laryngoscope"},{"issue":"4","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2559.2011.03937.x","volume":"59","author":"C Weiler","year":"2011","unstructured":"Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, et al. Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology. 2011;59(4):741\u201350.","journal-title":"Histopathology"},{"issue":"9","key":"1353_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/hed.1100","volume":"23","author":"KD Olsen","year":"2001","unstructured":"Olsen KD, Lewis JE. Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck. 2001;23(9):705\u201312.","journal-title":"Head Neck"},{"key":"1353_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9:217\u201322 [CrossRef] [PubMed].","journal-title":"J Epidemiol Glob Health"},{"key":"1353_CR19","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2004.040","volume-title":"Comprehensive search for cysteine cathepsins in the human genome","author":"A Rossi","year":"2004","unstructured":"Rossi A, Deveraux Q, Turk B, Sali A. Comprehensive search for cysteine cathepsins in the human genome. 2004."},{"key":"1353_CR20","first-page":"628","volume":"6","author":"AF Abdel-Magid","year":"2015","unstructured":"Abdel-Magid AF. Inhibition of Cathepsin K: a novel and promising treatment for osteoporosis. ACS Publications. 2015;6:628\u20139.","journal-title":"ACS Publications"},{"issue":"21","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","volume":"271","author":"FH Drake","year":"1996","unstructured":"Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but Not Cathepsins B, L, or S, is abundantly expressed in human osteoclasts (\u2217). J Biol Chem. 1996;271(21):12511\u20136.","journal-title":"J Biol Chem"},{"issue":"8","key":"1353_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","volume":"7","author":"AG Costa","year":"2011","unstructured":"Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7(8):447\u201356.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1359\/jbmr.2003.18.2.222","volume":"18","author":"K Brubaker","year":"2003","unstructured":"Brubaker K, Vessella R, True L, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003;18(2):222\u201330.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1353_CR24","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3390\/cancers13102441","volume":"13","author":"A Cali\u00f2","year":"2021","unstructured":"Cali\u00f2 A, Brunelli M, Gobbo S, Argani P, Munari E, Netto G, et al. Cathepsin K: a novel diagnostic and predictive biomarker for renal tumors. Cancers. 2021;13(10):2441.","journal-title":"Cancers"},{"issue":"8","key":"1353_CR25","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.3390\/curroncol29080471","volume":"29","author":"D Qian","year":"2022","unstructured":"Qian D, He L, Zhang Q, Li W, Tang D, Wu C, Yang F, Li K, Zhang H. Cathepsin K: a versatile potential biomarker and therapeutic target for various cancers. Curr Oncol. 2022;29(8):5963\u201387. https:\/\/doi.org\/10.3390\/curroncol29080471.","journal-title":"Curr Oncol"},{"issue":"1","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","volume":"11","author":"RR Seethala","year":"2017","unstructured":"Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of head and neck tumors: tumors of the salivary gland. Head Neck Pathol. 2017;11(1):55\u201367.","journal-title":"Head Neck Pathol"},{"key":"1353_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/his.12059","volume":"62","author":"Q Rao","year":"2013","unstructured":"Rao Q, Cheng L, Xia QY, Liu B, Li L, Shi QL, Shi SS, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Zhou XJ. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013;62:642\u201350.","journal-title":"Histopathology"},{"key":"1353_CR28","first-page":"1452","volume":"6","author":"Q Rao","year":"2013","unstructured":"Rao Q, Zhang XM, Tu P, Xia QY, Shen Q, Zhou XJ, Shi QL. Renal cell carcinomas with t(6;11) (p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol. 2013;6:1452\u20137.","journal-title":"Int J Clin Exp Pathol"},{"key":"1353_CR29","first-page":"1392","volume":"6","author":"QY Xia","year":"2013","unstructured":"Xia QY, Rao Q, Shen Q, Shi SS, Li L, Liu B, Zhang J, Wang YF, Shi QL, Wang JD, Ma HH, Lu ZF, Yu B, Zhang RS, Zhou XJ. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol. 2013;6:1392\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1353_CR30","first-page":"1132","volume":"7","author":"Q Rao","year":"2014","unstructured":"Rao Q, Wang Y, Xia QY, Shi SS, Shen Q, Tu P, Shi QL, Zhou XJ, Wu B. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions. Int J Clin Exp Pathol. 2014;7:1132\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1353_CR31","first-page":"38","volume":"11","author":"Y Sivaranjini","year":"2012","unstructured":"Sivaranjini Y, Angadi PV, Kumar GS. Immuno-histochemical evaluation of Cathepsin D in malignant salivary gland carcinomas. Gulf J Oncolog. 2012;11:38\u201344 PMID: 22227544.","journal-title":"Gulf J Oncolog"},{"key":"1353_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fonc.2018.00492","volume":"8","author":"M Zhang","year":"2018","unstructured":"Zhang M, Wu J, Yang X, Pang X, Li L, Wang S, Wu J, Tang Y, Liang X, Zheng M, Tang Y. Overexpression Cathepsin D contributes to perineural invasion of salivary adenoid cystic carcinoma. Front Oncol. 2018;8:492. https:\/\/doi.org\/10.3389\/fonc.2018.00492.","journal-title":"Front Oncol"},{"issue":"2","key":"1353_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1309\/AJCPDTRTO2Z4UEXD","volume":"139","author":"G Zheng","year":"2013","unstructured":"Zheng G, Martignoni G, Antonescu C, Montgomery E, Eberhart C, Netto G, et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol. 2013;139(2):151\u20139.","journal-title":"Am J Clin Pathol"},{"key":"1353_CR34","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22:2403\u201314 [CrossRef].","journal-title":"World J Gastroenterol"},{"key":"1353_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13104-015-1284-8","volume":"8","author":"J Christensen","year":"2015","unstructured":"Christensen J, Shastri VP. Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K. BMC Res Notes. 2015;8:322 [CrossRef].","journal-title":"BMC Res. Notes"},{"key":"1353_CR36","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1038\/s41598-019-43924-x","volume":"9","author":"L Li","year":"2019","unstructured":"Li L, Zhu Z, Zhao Y, Zhang Q, Wu X, Miao B, Cao J, Fei S. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Sci Rep. 2019;9:7827 [CrossRef].","journal-title":"Sci Rep"},{"key":"1353_CR37","doi-asserted-by":"publisher","first-page":"e0211968","DOI":"10.1371\/journal.pone.0211968","volume":"14","author":"PT Makondi","year":"2019","unstructured":"Makondi PT, Wei PL, Huang CY, Chang YJ. Development of novel predictive miRNA\/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach. PLoS One. 2019;14:e0211968 [CrossRef].","journal-title":"PLoS One"},{"key":"1353_CR38","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/jid.2008.63","volume":"128","author":"MJ Quintanilla-Dieck","year":"2008","unstructured":"Quintanilla-Dieck MJ, Codriansky K, R\u00fcnger TM, Bhawan J, R\u00fcnger TM. Cathepsin K in melanoma invasion. J Investig Dermatol. 2008;128:2281\u20138 [CrossRef].","journal-title":"J Investig Dermatol"},{"key":"1353_CR39","first-page":"711","volume":"32","author":"SJ Petricevic","year":"2017","unstructured":"Petricevic SJ, Pavlovic A, Durdov MG, Becic K, Durdov MG. Cathepsin K expression in melanoma is associated with metastases. Histol Histopathol. 2017;32:711\u20136.","journal-title":"Histol Histopathol"},{"key":"1353_CR40","first-page":"5386","volume":"57","author":"AJ Littlewood-Evans","year":"1997","unstructured":"Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans DB, Gallagher JA. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997;57:5386\u201390.","journal-title":"Cancer Res"},{"key":"1353_CR41","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","volume":"67","author":"C Le Gall","year":"2007","unstructured":"Le Gall C, Bellahc\u00e8ne A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Cl\u00e9zardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007;67:9894\u2013902 [CrossRef].","journal-title":"Cancer Res"},{"key":"1353_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1186\/s12885-016-2713-3","volume":"16","author":"E Guerra","year":"2016","unstructured":"Guerra E, Cimadamore A, Simeone P, Vacca G, Lattanzio R, Botti G, et al. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer. 2016;16:649. https:\/\/doi.org\/10.1186\/s12885-016-2713-3.","journal-title":"BMC Cancer"},{"key":"1353_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.biochi.2015.11.007","volume":"121","author":"O Achour","year":"2016","unstructured":"Achour O, Ashraf Y, Bridiau N, Kacem M, Poupard N, Bordenave-Juchereau S, et al. Alteration of cathepsin D trafficking induced by hypoxia and extracellular acidification in MCF-7 breast cancer cells. Biochimie. 2016;121:123\u201330. https:\/\/doi.org\/10.1016\/j.biochi.2015.11.007.","journal-title":"Biochimie"},{"key":"1353_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11030-015-9645-8","volume":"20","author":"HS Anantaraju","year":"2016","unstructured":"Anantaraju HS, Battu MB, Viswanadha S, Sriram D, Yogeeswari P. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers. Mol Divers. 2016;20:521\u201335. https:\/\/doi.org\/10.1007\/s11030-015-9645-8.","journal-title":"Mol Divers"},{"key":"1353_CR45","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1038\/s41598-019-41782-1","volume":"9","author":"AN Parks","year":"2019","unstructured":"Parks AN, Nahata J, Edouard NE, Temenoff JS, Platt MO. Sequential, but not concurrent, incubation of cathepsin K and L with type I collagen results in extended proteolysis. Sci Rep. 2019;9:5399 [CrossRef].","journal-title":"Sci Rep"},{"key":"1353_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1006\/bbrc.2001.5127","volume":"285","author":"S Corisdeo","year":"2001","unstructured":"Corisdeo S, Gyda M, Zaidi M, Moonga BS, Troen BR. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun. 2001;285:335\u20139 [CrossRef].","journal-title":"Biochem Biophys Res Commun"},{"key":"1353_CR47","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2353\/ajpath.2009.080906","volume":"175","author":"I Podgorski","year":"2009","unstructured":"Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol. 2009;175:1255\u201369 [CrossRef].","journal-title":"Am J Pathol"},{"key":"1353_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bonekey.2015.113","volume":"4","author":"E Terpos","year":"2015","unstructured":"Terpos E, Confavreux CB, Cl\u00e9zardin P. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep. 2015;4:744 [CrossRef].","journal-title":"Bonekey Rep"},{"key":"1353_CR49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-8587(13)70203-1","volume":"2","author":"LC Hofbauer","year":"2014","unstructured":"Hofbauer LC, Rachner TD, Coleman RE, Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2014;2:500\u201312 [CrossRef].","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1353_CR50","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jnci\/djs263","volume":"104","author":"R Coleman","year":"2012","unstructured":"Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012;104:1059\u201367 [CrossRef].","journal-title":"J Natl Cancer Inst"},{"key":"1353_CR51","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.redox.2019.101422","volume":"30","author":"SU Seo","year":"2020","unstructured":"Seo SU, Woo SM, Kim MW, Lee HS, Kim SH, Kang SC, Lee EW, Min KJ, Kwon TK. Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization. Redox Biol. 2020;30:101422 [CrossRef].","journal-title":"Redox Biol"},{"key":"1353_CR52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.trecan.2016.10.006","volume":"2","author":"Y Guri","year":"2016","unstructured":"Guri Y, Hall MN. mTOR Signaling confers resistance to targeted cancer drugs. Trends Cancer. 2016;2:688\u201397 [CrossRef].","journal-title":"Trends Cancer"},{"key":"1353_CR53","first-page":"840","volume":"48","author":"QY Xia","year":"2019","unstructured":"Xia QY, Wang X, Wei X, Wang XT, Ma HH, Lu ZF, Rao Q. Eosinophilic solid and cystic renal cell carcinoma: clinicopathological analysis and molecular characterization. Zhonghua Bing Li Xue Za Zhi. 2019;48:840\u20135.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"1353_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PAS.0000000000001170","volume":"43","author":"YB Chen","year":"2019","unstructured":"Chen YB, Mirsadraei L, Jayakumaran G, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121\u201331 [CrossRef].","journal-title":"Am J Surg Pathol"},{"key":"1353_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41379-021-00923-6","volume":"35","author":"M Farca,s","year":"2022","unstructured":"Farca,s M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R, Williamson SR, Magi-Galluzzi C, Gill AJ, Tretiakova M, et al. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC\/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol. 2022;35:344\u201351 [CrossRef].","journal-title":"Mod Pathol"},{"key":"1353_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/01926230290168542","volume":"30","author":"KS McDorman","year":"2002","unstructured":"McDorman KS, Wolf DC. Use of the spontaneous TSC2 knockout (Eker) rat model of hereditary renal cell carcinoma for the study of renal carcinogens. Toxicol Pathol. 2002;30:675\u201380 [CrossRef].","journal-title":"Toxicol Pathol"},{"key":"1353_CR57","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-20-3979","volume":"81","author":"H Wu","year":"2021","unstructured":"Wu H, He D, Biswas S, Shafiquzzaman M, Zhou X, Charron J, Wang Y, Nayak BK, Habib SL, Liu H, et al. mTOR activation initiates renal cell carcinoma development by coordinating ERK and p38MAPK. Cancer Res. 2021;81:3174\u201386 [CrossRef].","journal-title":"Cancer Res"},{"key":"1353_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1568009611313020003","volume":"13","author":"DC Cho","year":"2013","unstructured":"Cho DC, Mier JW. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013;13:126\u201342 [CrossRef].","journal-title":"Curr Cancer Drug Targets"},{"key":"1353_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737140.2016.1109454","volume":"16","author":"A Coinu","year":"2016","unstructured":"Coinu A, Petrelli F, Barni S. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. Expert Rev Anticancer Ther. 2016;16:33\u201343 [CrossRef].","journal-title":"Expert Rev Anticancer Ther"},{"key":"1353_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1074\/jbc.M116.764761","volume":"292","author":"Q Dai","year":"2017","unstructured":"Dai Q, Xie F, Han Y, Ma X, Zhou S, Jiang L, Zou W, Wang J. Inactivation of regulatory-associated protein of mTOR (raptor)\/mammalian target of rapamycin complex 1 (mTORC1) signaling in osteoclasts increases bone mass by inhibiting osteoclast differentiation in mice. J Biol Chem. 2017;292:196\u2013204 [CrossRef].","journal-title":"J Biol Chem"},{"key":"1353_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2478\/v10042-009-0024-0","volume":"47","author":"W Naumnik","year":"2009","unstructured":"Naumnik W, Nikli \u2018nska W, Ossoli \u2018nska M, Chyczewska E. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy. Folia Histochem CytoBiol. 2009;47:207\u201313 [CrossRef].","journal-title":"Folia Histochem CytoBiol"},{"key":"1353_CR62","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2011.04.009","volume":"74","author":"R Wang","year":"2011","unstructured":"Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer. 2011;74:188\u201396 [CrossRef] [PubMed].","journal-title":"Lung Cancer"},{"key":"1353_CR63","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/molecules25184136","volume":"25","author":"H Yang","year":"2020","unstructured":"Yang H, Heyer J, Zhao H, Liang S, Guo R, Zhong L. The potential role of Cathepsin K in non-small cell lung cancer. Molecules. 2020;25:4136 [CrossRef] [PubMed].","journal-title":"Molecules"},{"key":"1353_CR64","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.7150\/jca.36636","volume":"11","author":"Z Tingting","year":"2020","unstructured":"Tingting Z, Xiaojing L, Junjun Q, Keqin H, Junjun Q. The antisense long noncoding RNA AGAP2-AS1 regulates cell proliferation and metastasis in epithelial ovarian cancer. J Cancer. 2020;11:5318\u201328 [CrossRef].","journal-title":"J Cancer"},{"issue":"8","key":"1353_CR65","doi-asserted-by":"publisher","first-page":"e70925","DOI":"10.1371\/journal.pone.0070925","volume":"8","author":"CC Bitu","year":"2013","unstructured":"Bitu CC, Kauppila JH, Bufalino A, Nurmenniemi S, Teppo S, et al. Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. PLoS One. 2013;8(8):e70925. https:\/\/doi.org\/10.1371\/journal.pone.0070925.","journal-title":"PLoS One"},{"issue":"12","key":"1353_CR66","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1245\/s10434-015-4454-y","volume":"22","author":"S Ali","year":"2015","unstructured":"Ali S, Bryant R, Palmer FL, DiLorenzo M, Shah JP, Patel SG, et al. Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol. 2015;22(12):4014\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"1353_CR67","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1245\/s10434-016-5356-3","volume":"23","author":"SJ Nam","year":"2016","unstructured":"Nam SJ, Roh J-L, Cho K-J, Choi S-H, Nam SY, Kim SY. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23(13):4376\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"S1","key":"1353_CR68","doi-asserted-by":"publisher","first-page":"E2041","DOI":"10.1002\/hed.24375","volume":"38","author":"M Haderlein","year":"2016","unstructured":"Haderlein M, Scherl C, Semrau S, Lettmaier S, Uter W, Neukam FW, et al. High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. Head Neck. 2016;38(S1):E2041\u20138.","journal-title":"Head Neck"},{"key":"1353_CR69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40880-019-0425-1","volume":"39","author":"X Zhang","year":"2019","unstructured":"Zhang X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun. 2019;39:76 [CrossRef].","journal-title":"Cancer Commun"},{"key":"1353_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","volume":"10","author":"AB Jensen","year":"2010","unstructured":"Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10:452\u20138 [CrossRef].","journal-title":"Clin Breast Cancer"},{"key":"1353_CR71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","volume":"34","author":"P Argani","year":"2010","unstructured":"Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, Reuter VE, Netto GJ. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34:1295\u2013303 [CrossRef].","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"1353_CR72","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2174\/0929867327666200330142432","volume":"28","author":"H Li","year":"2021","unstructured":"Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: mechanism, molecular target and current status on drug development. Curr Med Chem. 2021;28(8):1489\u2013507.","journal-title":"Curr Med Chem"},{"issue":"1","key":"1353_CR73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11914-011-0085-9","volume":"10","author":"S Boonen","year":"2012","unstructured":"Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012;10(1):73\u20139.","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"1353_CR74","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3892\/ijo.2019.4722","volume":"54","author":"JS Wu","year":"2019","unstructured":"Wu JS, Li ZF, Wang HF, Yu XH, Pang X, Wu JB, Wang SS, Zhang M, Yang X, Cao MX, Tang YJ, Liang XH, Zheng M, Tang YL. Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma. Int J Oncol. 2019;54(4):1233\u201344. https:\/\/doi.org\/10.3892\/ijo.2019.4722. Epub 2019 Feb 22. PMID: 30968153; PMCID: PMC6411368.","journal-title":"Int J Oncol"},{"issue":"4","key":"1353_CR75","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4103\/jomfp.jomfp_370_20","volume":"26","author":"M Mohan","year":"2022","unstructured":"Mohan M, Suresh R, Janardhanan M, Savithri V, Aravind T. Immunohistochemical analysis of cathepsin-D in benign and malignant salivary gland neoplasms. Evaluation of its role as a prognostic indicator. J Oral Maxillofac Pathol. 2022;26(4):589. https:\/\/doi.org\/10.4103\/jomfp.jomfp_370_20.","journal-title":"J Oral Maxillofac Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-023-01353-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:07:02Z","timestamp":1684300022000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-023-01353-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1186\/s13000-023-01353-5","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was approved by faculty of Dentistry ethics committee. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consents to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}